Literature DB >> 2456364

A monoclonal antibody specific for a common determinant of the human T cell receptor gamma/delta directly activates CD3+WT31- lymphocytes to express their functional program(s).

E Ciccone1, S Ferrini, C Bottino, O Viale, I Prigione, G Pantaleo, G Tambussi, A Moretta, L Moretta.   

Abstract

In an attempt to select mAbs specific for human TCR-gamma/delta, a polyclonal CD3+ 4-8-WT31- (TCR-gamma/delta+) cell line (MV1) was used for mice immunization. An mAb, termed BB3, reacted with MV1 cells but not with a large panel of CD3+ WT31+ (TCR-alpha/beta+) cell populations or clones. In addition, BB3 mAb reacted with the majority of CD3+ WT31- clones derived from six different donors. Double-color fluorescence experiments and FACS analysis showed that BB3+ cells were restricted to the CD3+ fraction of peripheral blood lymphocytes; in addition, in several donors the percentages (0.5-8% of total PBL) of BB3+ cells paralleled those of CD3+ WT31- cells. Surface molecules recognized by BB3 were susceptible to antibody-induced modulation; in addition, cell treatment with either BB3 or anti-CD3 mAb caused the simultaneous downregulation of the two molecules. That BB3 molecules are physically linked to CD3 antigen was further supported by immunoprecipitation experiments. Thus, under conditions that preserve the TCR-CD3 association, both BB3 and anti-CD3 mAb precipitated from 125I-labeled MV1 cells the same set of molecules. These consisted in the 18-28-kD CD3 molecules and in three bands of approximately 44, 42, and 38 kD under reducing conditions. When cell lysis was performed in 1% NP-40, the molecules immunoprecipitated by BB3 mAb were represented by an 80-kD band under nonreducing conditions, which resolved, under reducing conditions, in the three 44-, 42-, and 38-kD bands. Similar disulphide-linked forms of the TCR molecules were revealed in all of the other eight CD3+ WT31- BB3+ clones analyzed. Analysis of TCR molecules by electrophoresis (NEPHGE) showed that BB3 or anti-CD3 precipitated a 44-kD molecule displaying a basic PI (approximately 7.5) and two more acidic proteins (PI approximately 6) with a mol mass of 42 and 38 kD. Studies aimed to define whether stimuli directly acting on TCR-gamma/delta could induce CD3+ WT31- cell activation revealed that (a) In the presence of PMA, soluble BB3 mAb induced IL-2 production by MV1 cell line and by three other CD3+ WT31- BB3+ clones analyzed. (b) BB3 mAb-producing hybridoma used as triggering target, was efficiently lysed by CD3+ WT31- BB3+ effector cells (but not by CD3+ WT31+ BB3- conventional CTL). (c) Soluble BB3 mAb induced CD3+ WT31- BB3+ effector cells to lyse the Fc receptor-positive P815 target cells. (d) BB3-TCR-gamma/delta interaction on CD3+ WT31- BB3+ cells induced a rapid increase of [Ca2+]i levels, similar to that observed in response to anti-CD3 mAbs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2456364      PMCID: PMC2188975          DOI: 10.1084/jem.168.1.1

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

1.  High resolution two-dimensional electrophoresis of basic as well as acidic proteins.

Authors:  P Z O'Farrell; H M Goodman; P H O'Farrell
Journal:  Cell       Date:  1977-12       Impact factor: 41.582

2.  Cross-linking of human T cell receptor proteins: association between the T cell idiotype beta subunit and the T3 glycoprotein heavy subunit.

Authors:  M B Brenner; I S Trowbridge; J L Strominger
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

3.  Analysis of signal transducing mechanisms in CD3+ CD4- CD8- cells expressing the putative T cell receptor gamma gene product.

Authors:  G Pantaleo; S Ferrini; M R Zocchi; C Bottino; R Biassoni; L Moretta; A Moretta
Journal:  J Immunol       Date:  1987-12-01       Impact factor: 5.422

4.  An alternative pathway of T-cell activation: a functional role for the 50 kd T11 sheep erythrocyte receptor protein.

Authors:  S C Meuer; R E Hussey; M Fabbi; D Fox; O Acuto; K A Fitzgerald; J C Hodgdon; J P Protentis; S F Schlossman; E L Reinherz
Journal:  Cell       Date:  1984-04       Impact factor: 41.582

5.  Direct demonstration of the clonogenic potential of every human peripheral blood T cell. Clonal analysis of HLA-DR expression and cytolytic activity.

Authors:  A Moretta; G Pantaleo; L Moretta; J C Cerottini; M C Mingari
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

6.  Frequency and surface phenotype of human T lymphocytes producing interleukin 2. Analysis by limiting dilution and cell cloning.

Authors:  A Moretta
Journal:  Eur J Immunol       Date:  1985-02       Impact factor: 5.532

7.  Externally disposed plasma membrane proteins. I. Enzymatic iodination of mouse L cells.

Authors:  A L Hubbard; Z A Cohn
Journal:  J Cell Biol       Date:  1975-02       Impact factor: 10.539

8.  A novel subset of human lymphocytes with a T cell receptor-gamma complex.

Authors:  S Jitsukawa; F Faure; M Lipinski; F Triebel; T Hercend
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

9.  Clonotypic structures involved in antigen-specific human T cell function. Relationship to the T3 molecular complex.

Authors:  S C Meuer; K A Fitzgerald; R E Hussey; J C Hodgdon; S F Schlossman; E L Reinherz
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

10.  Quantitative assessment of the pool size and subset distribution of cytolytic T lymphocytes within human resting or alloactivated peripheral blood T cell populations.

Authors:  A Moretta; G Pantaleo; L Moretta; M C Mingari; J C Cerottini
Journal:  J Exp Med       Date:  1983-08-01       Impact factor: 14.307

View more
  29 in total

1.  Increase of lymphocytes bearing the gamma/delta T cell receptor in the jejunum of patients with dermatitis herpetiformis.

Authors:  E Savilahti; T Reunala; M Mäki
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

2.  Growth features of T-cell receptor gamma/delta-positive cell clones.

Authors:  G Arancia; W Malorni; F Iosi; D Zarcone; G Cerruti; A Moretta; C E Grossi
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 3.  Newly identified gamma delta and beta delta T-cell receptors.

Authors:  F Hochstenbach; M B Brenner
Journal:  J Clin Immunol       Date:  1990-01       Impact factor: 8.317

Review 4.  The role of gamma delta T cells in the normal and disordered immune system.

Authors:  B Bröker; P M Lydyard; F Emmrich
Journal:  Klin Wochenschr       Date:  1990-05-17

5.  Gamma delta T-cell receptor repertoire in human peripheral blood and thymus.

Authors:  H Vietor; F Koning
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

6.  Coexpression of Fc gamma receptor IIIA and interleukin-2 receptor beta chain by a subset of human CD3+/CD8+/CD11b+ lymphocytes.

Authors:  S Zupo; L Azzoni; R Massara; A D'Amato; B Perussia; M Ferrarini
Journal:  J Clin Immunol       Date:  1993-05       Impact factor: 8.317

7.  Stimulation of synovial fluid mononuclear cells with the human 65-kD heat shock protein or with live enterobacteria leads to preferential expansion of TCR-gamma delta+ lymphocytes.

Authors:  E Hermann; A W Lohse; W J Mayet; R van der Zee; W Van Eden; P Probst; T Poralla; K H Meyer zum Büschenfelde; B Fleischer
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

8.  Involvement of the interleukin 4 pathway in the generation of functional gamma delta T cells from human pro-T cells.

Authors:  A Bárcena; M J Sánchez; J L de la Pompa; M L Toribio; G Kroemer; C Martínez-A
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

9.  Predominant expansion of V gamma 9/V delta 2 T cells in a tularemia patient.

Authors:  T Sumida; T Maeda; H Takahashi; S Yoshida; F Yonaha; A Sakamoto; H Tomioka; T Koike; S Yoshida
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

10.  Increase in TCR gamma delta T lymphocytes in synovia from rheumatoid arthritis patients with active synovitis.

Authors:  M R Jacobs; B F Haynes
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.